Cassava sciences reports positive preclinical study evaluating simufilam for tsc-related epilepsy

Austin, texas, aug. 04, 2025 (globe newswire) --  cassava sciences, inc. (nasdaq: sava, “cassava”, the “company”), a clinical-stage biotechnology company focused on developing novel treatments for central nervous system (cns) disorders, today reported positive preclinical results of a study evaluating simufilam in a well-accepted mouse model of tuberous sclerosis complex (tsc)-related epilepsy.
SAVA Ratings Summary
SAVA Quant Ranking